News

Under the deal, Concordia will buy substantially all of the commercial assets of Covis Pharma and Covis Injectables, including 18 branded and authorized generic products. Covis drug portfolio

The Emergent-developed MOR209/ES414 molecule is an immunotherapeutic protein, which has shown in preclinical in vitro and in vivo studies its ability to redirect T-cell cytotoxicity towards cells expressing

Sandoz, a Novartis company, is the first in the US to receive the approval through the new FDA biosimilars pathway established under the Biologics Price Competition and Innovation

The companies will conduct a study assess the clinical accuracy of spectral imaging technology with low radiation dose to measure breast density, potentially increasing accuracy of cancer detection

The anti-blood clotting drug apixaban can be used to treat venous thromboembolism (VTE) in adults, which is used to describe deep vein thrombosis (DVT) and pulmonary embolism (PE).

People familiar with the matter were reported by Reuters as saying that GSK confirmed the dismissal was for wrongdoing and misconduct that took place before mid-2013. However, the

The prodrug for isavuconazole, Cresemba has been approved for use in patients aged 18 years and above in the treatment of zygomycosis, which are life-threatening fungal infections predominantly

Under the terms of the agreement, TG Therapeutics will make an up-front payment as well as make development and sales-based milestone payments and will pay a tiered single

The grant has been given to clinically advance Irofulven for the treatment of metastatic castration resistant prostrate cancer (mCRPC) by utilising a highly predictive biomarker for the drug